Back to search
FDAFDA · Food and drugs·Recall number D-0092-2026

Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for Extension Health and Synergy Wellness 60mg, 10mL vial lyophilized.

Published October 15, 2025 · Recall initiated: July 30, 2025

Summary

FDA records drug Class II recall D-0092-2026, published October 15, 2025 and initiated July 30, 2025. Recalling firm: GenoGenix LLC; Status: Ongoing; Lot: Lots GG012925-005, GG021125-003, within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
GenoGenix LLC
Distributor
US Nationwide.
Lot
Lots GG012925-005, GG021125-003, within expiry.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for Extension Health and Synergy Wellness 60mg, 10mL vial lyophilized. recalled?

Yes. FDA published recall D-0092-2026 on October 15, 2025. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter